Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chengdu Kanghong Pharmaceutical Group Co., Ltd engages in the research, development, manufacture, and distribution of medicine for ophthalmic, neuropsychiatric and other applications in China. It also develops a pipeline of clinical and pre-clinical programs for ophthalmology, CNS, oncology, and common disease. The company was founded in 1996 and is based in Chengdu, China.
Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.055x
Based on the latest financial reports, Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) has a cash flow conversion efficiency ratio of 0.055x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥504.02 Million) by net assets (CN¥9.15 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Chengdu Kanghong Pharmaceuticals Group Co Ltd - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how Chengdu Kanghong Pharmaceuticals Group Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Chengdu Kanghong Pharmaceuticals Group Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chengdu Kanghong Pharmaceuticals Group Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Endo, Inc.
OTCQX:NDOI
|
0.001x |
|
Sabine Royalty Trust
NYSE:SBR
|
8.048x |
|
Lier Chemical Co Ltd
SHE:002258
|
0.035x |
|
Tompkins Financial Corporation
NYSE MKT:TMP
|
0.044x |
|
Micro Tech Nanjing Co Ltd
SHG:688029
|
0.042x |
|
Lincoln Educational Services
NASDAQ:LINC
|
0.218x |
|
Pilot Corporation
OTCGREY:POGHF
|
N/A |
|
Bangchak Corporation Public Company Limited
BK:BCP-R
|
0.054x |
Annual Cash Flow Conversion Efficiency for Chengdu Kanghong Pharmaceuticals Group Co Ltd (2009–2024)
The table below shows the annual cash flow conversion efficiency of Chengdu Kanghong Pharmaceuticals Group Co Ltd from 2009 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥8.65 Billion | CN¥1.41 Billion | 0.163x | +4.69% |
| 2023-12-31 | CN¥7.81 Billion | CN¥1.22 Billion | 0.156x | +16.44% |
| 2022-12-31 | CN¥6.91 Billion | CN¥925.15 Million | 0.134x | +65.50% |
| 2021-12-31 | CN¥6.10 Billion | CN¥494.11 Million | 0.081x | +70.45% |
| 2020-12-31 | CN¥5.76 Billion | CN¥273.32 Million | 0.047x | -72.98% |
| 2019-12-31 | CN¥4.62 Billion | CN¥812.15 Million | 0.176x | +104.58% |
| 2018-12-31 | CN¥4.08 Billion | CN¥350.88 Million | 0.086x | -60.30% |
| 2017-12-31 | CN¥3.54 Billion | CN¥766.86 Million | 0.216x | -25.72% |
| 2016-12-31 | CN¥2.90 Billion | CN¥846.35 Million | 0.291x | +52.64% |
| 2015-12-31 | CN¥2.52 Billion | CN¥481.97 Million | 0.191x | +5.59% |
| 2014-12-31 | CN¥1.61 Billion | CN¥291.38 Million | 0.181x | -24.65% |
| 2013-12-31 | CN¥1.39 Billion | CN¥333.31 Million | 0.240x | -5.84% |
| 2012-12-31 | CN¥1.11 Billion | CN¥281.84 Million | 0.255x | +41.29% |
| 2011-12-31 | CN¥936.39 Million | CN¥168.86 Million | 0.180x | -17.63% |
| 2010-12-31 | CN¥624.85 Million | CN¥136.79 Million | 0.219x | +8.98% |
| 2009-12-31 | CN¥539.75 Million | CN¥108.42 Million | 0.201x | -- |